Key Speakers and Presentations released for the 14th Annual RNA Therapeutics Conference

Top Quote SAE Media Group reports: ahead of the conference in February 2023, a snapshot or key speakers and presentations are released. End Quote
  • (1888PressRelease) December 13, 2022 - SAE Media Group’s 14th Annual RNA Therapeutics Conference will welcome expert speakers from big pharma companies to bring together cutting-edge discussions in the developments and challenges in the RNA Therapeutics field. The conference will take place on 8 – 9 February 2023 in London UK – live and in person.

    The RNA therapeutics industry has grown at an exponential rate in recent years, with an increased spotlight following the industry’s leading role in developing vaccines against COVID-19 in response to the global pandemic.

    RNAi continues to be a key focus of the event, in combination with RNA AI modelling and the next generation of RNA novel RNA modalities, including self-amplifying RNAs, small activating RNAs, circular RNAs and long non-coding RNAs.

    The RNA therapeutics conference this year will be covering an industry outlook of the RNA therapeutic field, a review of mRNA-based therapies, advancements in AI modelling, an update on RNAi and a more in-depth review of the next generation of novel RNA modalities.

    Register by 16 December to save £100 and take advantage of the early bird offer via

    SAE Media Group have released a snapshot of the speakers and sessions that will be featured during the two-day conference, please see below:

    Featured Key Conference Speakers:
    • Tamar Grossman, Vice President, Global Head of RNA and Targeted Therapeutics, The Janssen Pharmaceutical Companies of Johnson & Johnson
    • Joseph Martinelli, Senior Director Genetic Medicine, Eli Lilly
    • Ying Yu, Associated Director, AbbVie
    • Martin Akerman, Chief Technical Officer, Envisagenics
    • Shalini Andersson, Vice President Oligonucleotide Discovery, AstraZeneca
    • Souphalone Luangsay, Senior Principal Scientist, Roche

    Key Sessions include

    AI/ML Developed RNA Therapeutics for Neurodegenerative Diseases
    • Overcoming in-silico modeling challenges for neurodegenerative diseases
    • How Envisagenics’ SpliceCore platform can be used in designing antisense oligonucleotides
    • Translational R&D from in-silico to in-vitro for potential ASO candidates in neurodegenerative diseases
    Martin Akerman, Chief Technology Officer, Envisagenics

    Genetic Medicine: State of The Art, Frontiers and Current Research
    • Addressing key challenges at the forefront of the next generation of genetic medicines
    • The role of Nucleic acid innovation in the development of RNA therapeutics
    • Exploring delivery innovation as a crucial component in the advancement of RNA therapies
    Joseph Martinelli, Executive Director, Eli Lilly

    Visit the website to view the full agenda and speaker line-up at:

    Proudly sponsored by: Abzu, eTheRNA, Roche, Sartorius BIA Separations
    Exhibitors: Euroapi, PolyPeptide, Symbiosis

    For sponsorship enquiries contact Andrew Gibbons at
    andrew.gibbons ( @ ) saemediagroup dot com or +44 (0) 20 7827 6156

    For media enquiries contact Marketing, Lamprini Balasi at
    lamprini.balasi ( @ ) saemediagroup dot com or +44 (0) 20 7827 6732

    14th Annual RNA Therapeutics
    8 – 9 February 2023
    London, UK
    Register by 16 December 2022 and SAVE £100!

    About SAE Media Group Conferences:
    SAE Media Group Conferences connects global communities with focused networking conferences. We provide our customers with solutions through industry knowledge and collaboration that enables our attendees to return to their organisations better equipped to overcome their key business challenges. Our key events focus on Defence and Aerospace, Pharmaceutical and Medical. Each year we bring together over 5,000 senior business professionals at our conferences.

    SAE Media Group (SMG), a subsidiary of SAE International, reports the latest technology breakthroughs and design innovations to a global audience of nearly 1,000,000 engineers, researchers, and business managers. SMG provides critical information these professionals need to develop new and improved products and services.

  • FB Icon Twitter Icon In-Icon
Contact Information